...at NIH” ). Serentrix gained rights to its lead candidate and a backup compound from PharmEste...
...PROFILE Serentrix LLC Exton, Penn. Technology: Small molecule TRPV1 antagonists for pain Origin of technology: PharmEste...

...Ario acquired transient receptor potential A1 (TrpA1) antagonist assets previously owned by PharmEste. The assets include...
...to treat asthma. Ario declined to disclose financial details, and PharmEste could not be reached. PharmEste...